secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-05-19T20:30:03+00:00
Accession:  0001628280-26-036492
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026
--------------------------------------------------------------------------------

- Dr. Angelov brings two decades of industry experience including roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.
- Annual base salary of $425,000, $50,000 signing bonus paid in two tranches, and eligibility for annual discretionary bonus (target 45% of salary).
- Inducement grant of 150,000 stock options at $0.5955 per share, vesting over 4 years with 25% cliff at one year.
- Dr. Angelov is board-certified in psychiatry and holds an MBA from Wharton; will lead clinical development for Vistagen's pherine pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/0001628280-26-036492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/vtgn-20260518.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-036492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer